Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

LabCorp and Vanda Pharmaceuticals form alliance to offer genetic tests

Laboratory Corporation Of America : 06 June, 2008  (Company News)
Laboratory Corporation of America (LabCorp) and Vanda Pharmaceuticals has announced an exclusive alliance to develop and commercialise a series of diagnostic tests for genetic markers identified by Vanda in the course of its clinical development of Fanapta (iloperidone), a novel atypical antipsychotic drug candidate under FDA review for the treatment of schizophrenia.
Vanda has identified a series of pharmacogenetic markers during its development of Fanapta, and the company continues its pioneering work in this area. Under the terms of the collaboration, LabCorp will be Vanda's exclusive commercialisation partner for tests for genetic markers of the Fanapta programme.

'Working with innovative companies like Vanda to commercialise predictive medicine tests is a critical strategic focus for LabCorp,' said Andrew J Conrad, PhD, chief scientist and global head of clinical trials for LabCorp. 'This collaboration is an example of our commitment to the advancement of personalised medicine and represents a successful translation of a research based Assay into a valuable diagnostic test. This relationship is consistent with our focus on companion diagnostics.'

'We are pleased to be collaborating with LabCorp in this important effort,' said Mihael H Polymeropoulos, MD, chief executive officer of Vanda Pharmaceuticals. 'LabCorp's diagnostic development expertise, world-class testing capabilities, and national distribution network make them an ideal choice.'

Schizophrenia is a chronic, severe, and disabling mental disorder that affects more than two million Americans and approximately one percent of the world's adult population. Patients suffering from schizophrenia exhibit a range of symptoms, including: positive symptoms, such as hallucinations and delusions; negative symptoms, such as emotional withdrawal; and cognitive symptoms associated with significant impairment in social and occupational functioning.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo